Theravance Biopharma Inc
NASDAQ:TBPH

Watchlist Manager
Theravance Biopharma Inc Logo
Theravance Biopharma Inc
NASDAQ:TBPH
Watchlist
Price: 17.81 USD -1.71% Market Closed
Market Cap: 902.4m USD

Intrinsic Value

The intrinsic value of one TBPH stock under the Base Case scenario is 8.48 USD. Compared to the current market price of 17.81 USD, Theravance Biopharma Inc is Overvalued by 52%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TBPH Intrinsic Value
8.48 USD
Overvaluation 52%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Theravance Biopharma Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about TBPH?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is TBPH valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Theravance Biopharma Inc.

Explain Valuation
Compare TBPH to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about TBPH?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Theravance Biopharma Inc

Current Assets 354.7m
Cash & Short-Term Investments 329.7m
Receivables 18.3m
Other Current Assets 6.8m
Non-Current Assets 60.8m
Long-Term Investments 3m
PP&E 31.7m
Other Non-Current Assets 26m
Current Liabilities 37.4m
Accounts Payable 2.2m
Accrued Liabilities 31.1m
Other Current Liabilities 4.1m
Non-Current Liabilities 145.4m
Long-Term Debt 32.2m
Other Non-Current Liabilities 113.2m
Efficiency

Free Cash Flow Analysis
Theravance Biopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Theravance Biopharma Inc

Revenue
80.3m USD
Operating Expenses
-113.1m USD
Operating Income
-32.8m USD
Other Expenses
62.2m USD
Net Income
29.3m USD
Fundamental Scores

TBPH Profitability Score
Profitability Due Diligence

Theravance Biopharma Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
ROIC is Increasing
Strong 3Y Average Net Margin
Exceptional Net Margin
43/100
Profitability
Score

Theravance Biopharma Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

TBPH Solvency Score
Solvency Due Diligence

Theravance Biopharma Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
63/100
Solvency
Score

Theravance Biopharma Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TBPH Price Targets Summary
Theravance Biopharma Inc

Wall Street analysts forecast TBPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TBPH is 27.25 USD with a low forecast of 13.13 USD and a high forecast of 44.1 USD.

Lowest
Price Target
13.13 USD
26% Downside
Average
Price Target
27.25 USD
53% Upside
Highest
Price Target
44.1 USD
148% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Theravance Biopharma Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TBPH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

TBPH Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one TBPH stock?

The intrinsic value of one TBPH stock under the Base Case scenario is 8.48 USD.

Is TBPH stock undervalued or overvalued?

Compared to the current market price of 17.81 USD, Theravance Biopharma Inc is Overvalued by 52%.

Back to Top